Reports Q2 2023 total revenues of $338M, above the prior guidance range, net loss of $261M and adjusted EBITDA of $56M Updates FY 2023 guidance and prov...
QIAGEN announced the U.S. Food and Drug Administration (FDA) approval of its therascreen PDGFRA RGQ PCR kit (therascreen PDGFRA kit). This companion diagn...
Agilent Technologies Inc. (NYSE: A) announced the opening of a new full-scale Integrated Biology Center located at Monash University in Malaysia...
Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic enginee...
Chikungunya vaccine candidate met all the co-primary endpoints of the Phase 3 study and was shown to be highly immunogenic in the majority of subjects 22...
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, de...
Melinta Therapeutics, LLC announced the availability of REZZAYO™ (rezafungin for injection), for the treatment of candidemia and invasive candi...
Each year, millions of patients contract infectious diseases while in hospital. These HAIs not only lengthen hospital stays and utilize resources, such as ...
Through TrialHub's data intelligence gathering platform, EmVenio can easily identify optimal markets to attract clinical trial participants who are needed ...
A hallmark of many neurodegenerative disorders is the accumulation of damaged or abnormally folded proteins. The impact of such intracellular accumulations...
The partners continue working closely on matters concerning pending approval in the U.S. for AVT02, an interchangeable high-concentration biosimilar candid...
Collaboration Combines ImmunoGen's Proprietary Linker-Payload Technology with Antibodies Developed by ImmunoBiochem Agreement Grants ImmunoGen an Exclusiv...
The CHMP positive opinion will be considered by the European Commission. The European Commission decision on the approval is expected by the end of Se...
Magrolimab is a potential first-in-class, anti-CD47 immunotherapy with a clinical development program spanning ten potential indications including ongoing ...
© 2024 Biopharma Boardroom. All Rights Reserved.
